Live
- Open Network for Digital Commerce: Tirupati corporation to promote SHG groups products online marketing
- 4th T20I: India elect to bat first in series decider vs South Africa
- The Telangana Woman Sushma Thodety Shines in the UMB Pageant's ‘Mrs. India’ Competition
- Suspect arrested after firing shots near Israeli consulate in Istanbul
- IPL 2025: Pant, Iyer, Rahul, Buttler, Shami among most-priced as 571 players set for mega auction
- Delhi Mayor poll: Cross-voting shows AAP councillors’ frustration, says Congress leader Jitender Kochar
- NIA files fresh charges against Mizoram-based arms trafficker
- From appeasement to 'New India' pitch: Nadda credits PM Modi for changing style of politics
- Bihar liquor ban gave rise to unauthorised trade, means ‘big money’ for officials: Patna HC
- COP29 Presidency launches initiative to address climate change, humanitarian needs
India, EU to meet on Jan 18 in Brussels
India and EU are expected to meet on January 18 in Brussels to iron out issues related to the ban imposed by the latter on around 700 pharma products which were clinically tested by Hyderabad-based GVK Biosciences.
GVK Bio row
New Delhi : India and EU are expected to meet on January 18 in Brussels to iron out issues related to the ban imposed by the latter on around 700 pharma products which were clinically tested by Hyderabad-based GVK Biosciences. Accompanied by industry representatives from Pharmaceuticals Export Promotion Council (PHARMEXCIL), senior officials from the commerce ministry will be visiting Brussels next month.
"Several issues are likely to come up during the meeting, including GVK Biosciences," an official said. The ban imposed by the 28-nation bloc had led to deferment of talks in August between the two sides on the stalled free trade agreement, officially dubbed as Broadbased Investment and Trade Agreement (BTIA), to boost two-way commerce and investment. India had expressed disappointment on the development and stated that the decision was taken unilaterally. The EU had banned the marketing of around 700 generic medicines for alleged manipulation of clinical trials.
